Sugammadex - Revision history

Beren85: /* Pediatric Dosing */

2024-04-16T21:45:12Z

Pediatric Dosing

← Revisión anterior		Revisión del 21:45 16 abr 2024
Línea 13:		Línea 13:

	==Pediatric Dosing==		==Pediatric Dosing==
	*~~No approved dosing or usage~~		*16 mg/kg for pediatric patients aged 2 years and older

	==Special Populations==		==Special Populations==

ClaireLewis: /* References */

2019-09-23T22:36:45Z

References

← Revisión anterior		Revisión del 22:36 23 sep 2019
Línea 66:		Línea 66:

	[[Category:Pharmacology]]		[[Category:Pharmacology]]
			[[Category:Toxicology]] [[Category:Critical Care]]

Mrosen5506: /* Adverse Reactions */

2018-08-12T18:39:14Z

Adverse Reactions

← Revisión anterior		Revisión del 18:39 12 ago 2018
Línea 38:		Línea 38:
	===Serious===		===Serious===
	*[[Anaphylaxis]] (0.3%), hypersensitivity reaction		*[[Anaphylaxis]] (0.3%), hypersensitivity reaction
	*Bradycardia (1-5%)		*Bradycardia/Asystole (1-5%) <ref>Bhavani, S. S. (2018). Severe bradycardia and asystole after sugammadex. British Journal of Anaesthesia, 121(1), 95–96.</ref>
	*[[Prolonged QT]]		*[[Prolonged QT]]

Línea 46:		Línea 46:
	*Coughing		*Coughing
	*Extremity pain		*Extremity pain
	*Parosmia, hypoesthesia		*Parosmia, hypoesthesia

	==Pharmacology==		==Pharmacology==

Rossdonaldson1: /* Contraindications */

2017-01-05T03:19:59Z

Contraindications

← Revisión anterior		Revisión del 03:19 5 ene 2017
Línea 26:		Línea 26:
	*Adult: Unknown		*Adult: Unknown
	*Pediatric: Unknown		*Pediatric: Unknown

			==Indications==
			*[[Rocuronium]] or [[vecuronium]] reversal

	==Contraindications==		==Contraindications==

Rossdonaldson1 at 03:18, 5 January 2017

2017-01-05T03:18:47Z

← Revisión anterior		Revisión del 03:18 5 ene 2017
Línea 8:		Línea 8:

	==Adult Dosing==		==Adult Dosing==
	'''IV bolus injection infused over 10 seconds via central or peripheral line with 16 mg/kg will reverse a single 1.2 mg/kg dose of rocuronium in approximately 3 minutes.'''<ref>Abrishami A et al. "Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade". Cochrane Database of Systematic Reviews. 2009(4). CD007362. doi:10.1002/14651858.CD007362.pub2. PMID 19821409</ref>		'''IV bolus injection infused over 10 seconds via central or peripheral line with 16 mg/kg will reverse a single 1.2 mg/kg dose of [[rocuronium]] in approximately 3 minutes.'''<ref>Abrishami A et al. "Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade". Cochrane Database of Systematic Reviews. 2009(4). CD007362. doi:10.1002/14651858.CD007362.pub2. PMID 19821409</ref>
	*4 mg/kg if patient has no twitch responses to train-of-four and emergent reverse is not needed		*4 mg/kg if patient has no twitch responses to train-of-four and emergent reverse is not needed
	*2mg/kg if patient has a second twitch after train of four and no emergent reversal is needed		*2mg/kg if patient has a second twitch after train of four and no emergent reversal is needed

	==Pediatric Dosing==		==Pediatric Dosing==
	*No approved dosing or usage		*No approved dosing or usage

	==Special Populations==		==Special Populations==
	*[[Drug Ratings in Pregnancy\|Pregnancy Rating]]: There are no data on use in pregnant women		*[[Drug Ratings in Pregnancy\|Pregnancy Rating]]: There are no data on use in pregnant women
	*[[Lactation risk categories\|Lactation risk]]: Unknown		*[[Lactation risk categories\|Lactation risk]]: Unknown

	===Renal Dosing===		===Renal Dosing===
	*Adult: Unknown		*Adult: Unknown
	*Pediatric: Unknown		*Pediatric: Unknown

	===Hepatic Dosing===		===Hepatic Dosing===
	*Adult: Unknown		*Adult: Unknown
Línea 28:		Línea 32:
	==Adverse Reactions==		==Adverse Reactions==
	Adverse effects are described in the anesthesia literature and the most serious side effect is in patients with a known hypersensitivity to Sugammadex<ref>Park J. Benefits and risks of sugammadex. Korean J Anesthesiol. 2015 Feb; 68(1): 1–2.</ref>		Adverse effects are described in the anesthesia literature and the most serious side effect is in patients with a known hypersensitivity to Sugammadex<ref>Park J. Benefits and risks of sugammadex. Korean J Anesthesiol. 2015 Feb; 68(1): 1–2.</ref>

	===Serious===		===Serious===
	*Anaphylaxis (0.3%), hypersensitivity reaction		*[[Anaphylaxis]] (0.3%), hypersensitivity reaction
	*Bradycardia (1-5%)		*Bradycardia (1-5%)
	*Prolonged QT		*[[Prolonged QT]]

	===Common===		===Common===
	*Nausea/vomiting		*[[Nausea/vomiting]]
	*Headache		*[[Headache]]
	*Coughing		*Coughing
	*Extremity pain		*Extremity pain
Línea 44:		Línea 50:
	*Metabolism:		*Metabolism:
	*Excretion: Renal		*Excretion: Renal

	==Mechanism of Action==		==Mechanism of Action==
	*Encapsulates rocuronium or vecuronium in plasma, reducing the amount of neuromuscular blocking agent available to bind to nicotinic receptors in the neuromuscular junction and thereby reversing neuromuscular blockade		*Encapsulates [[rocuronium]] or [[vecuronium]] in plasma, reducing the amount of neuromuscular blocking agent available to bind to nicotinic receptors in the neuromuscular junction and thereby reversing neuromuscular blockade

	==Comments==		==Comments==

Mholtz at 00:36, 25 December 2016

2016-12-25T00:36:22Z

← Revisión anterior		Revisión del 00:36 25 dic 2016
Línea 8:		Línea 8:

	==Adult Dosing==		==Adult Dosing==
	'''IV bolus injection infused over 10 seconds via central or peripheral line with 16 mg/kg will reverse a single 1.2 mg/kg dose of rocuronium in approximately 3 minutes.'''		'''IV bolus injection infused over 10 seconds via central or peripheral line with 16 mg/kg will reverse a single 1.2 mg/kg dose of rocuronium in approximately 3 minutes.'''<ref>Abrishami A et al. "Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade". Cochrane Database of Systematic Reviews. 2009(4). CD007362. doi:10.1002/14651858.CD007362.pub2. PMID 19821409</ref>
	*4 mg/kg if patient has no twitch responses to train-of-four and emergent reverse is not needed		*4 mg/kg if patient has no twitch responses to train-of-four and emergent reverse is not needed
	*2mg/kg if patient has a second twitch after train of four and no emergent reversal is needed		*2mg/kg if patient has a second twitch after train of four and no emergent reversal is needed
Línea 49:		Línea 49:
	==Comments==		==Comments==
	*Sugammadex is only FDA approved for reversal for patients undergoing surgery. The drug has been used in Europe since 2008<ref>[http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000885/WC500052309.pdf Assessment Report for Bridion. European Medicines Agency]</ref>		*Sugammadex is only FDA approved for reversal for patients undergoing surgery. The drug has been used in Europe since 2008<ref>[http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000885/WC500052309.pdf Assessment Report for Bridion. European Medicines Agency]</ref>

	==See Also==		==See Also==

	==References==		==References==
	Abrishami A et al. "Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade". Cochrane Database of Systematic Reviews. 2009(4). CD007362. doi:10.1002/14651858.CD007362.pub2. PMID 19821409
	<references/>		<references/>

	[[Category:Pharmacology]]		[[Category:Pharmacology]]

ClaireLewis at 01:54, 11 December 2016

2016-12-11T01:54:41Z

← Revisión anterior		Revisión del 01:54 11 dic 2016
Línea 1:		Línea 1:
	==Administration==		==Administration==
	*Type/Class: γ-cyclodextrin		*Type/Class: γ-cyclodextrin, [[antidote]]
	*Dosage Forms:		*Dosage Forms:
	**200mg/2mL (100mg/mL)		**200mg/2mL (100mg/mL)
Línea 27:		Línea 27:

	==Adverse Reactions==		==Adverse Reactions==
	Adverse ~~affects~~ are described in the anesthesia literature and the most serious side effect is in patients with a known hypersensitivity to Sugammadex<ref>Park J. Benefits and risks of sugammadex. Korean J Anesthesiol. 2015 Feb; 68(1): 1–2.</ref>		Adverse effects are described in the anesthesia literature and the most serious side effect is in patients with a known hypersensitivity to Sugammadex<ref>Park J. Benefits and risks of sugammadex. Korean J Anesthesiol. 2015 Feb; 68(1): 1–2.</ref>
	===Serious===		===Serious===
	*Anaphylaxis (0.3%)		*Anaphylaxis (0.3%), hypersensitivity reaction
	*Bradycardia (1-5%)		*Bradycardia (1-5%)
			*Prolonged QT
	===~~Minor~~===		===Common===
			*Nausea/vomiting
			*Headache
	*Coughing		*Coughing
	*Extremity pain		*Extremity pain
	*Parosmia		*Parosmia, hypoesthesia
	*Hypoesthesia

	==Pharmacology==		==Pharmacology==
	~~Sugammadex can encapsulates rocuronium and vecuronium preventing binding to acetylcholine receptors and can reverse~~ paralysis in 3 minutes.		*Onset of action: reverses paralysis in ~3 minutes
	*Half-life:		*Half-life: 2h
	*Metabolism:		*Metabolism:
	*Excretion:		*Excretion: Renal
	==Mechanism of Action==		==Mechanism of Action==
	~~Sugammadex is a reversal~~ agent ~~that can~~ bind to ~~rocuronium~~ and ~~reverse paralysis. The molecule encapsulates rocuronium rather than~~ reversing paralysis via inhibition of [[acetylcholinesterase]] like [[neostigmine]]. The main use is in reversal of [[rocuronium]] or [[vecuronium]] induced paralysis after surgery<ref>Abrishami A et al. "Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade~~". Cochrane Database of Systematic Reviews. 2009(4). CD007362. doi:10.1002/14651858.CD007362.pub2. PMID 19821409</ref>~~		*Encapsulates rocuronium or vecuronium in plasma, reducing the amount of neuromuscular blocking agent available to bind to nicotinic receptors in the neuromuscular junction and thereby reversing neuromuscular blockade

	==Comments==		==Comments==
	*Sugammadex is only FDA approved for reversal for patients undergoing surgery. The drug has been used in Europe since 2008<ref>[http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000885/WC500052309.pdf Assessment Report for Bridion. European Medicines Agency]</ref>		*Sugammadex is only FDA approved for reversal for patients undergoing surgery. The drug has been used in Europe since 2008<ref>[http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000885/WC500052309.pdf Assessment Report for Bridion. European Medicines Agency]</ref>
Línea 50:		Línea 52:

	==References==		==References==
			Abrishami A et al. "Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade". Cochrane Database of Systematic Reviews. 2009(4). CD007362. doi:10.1002/14651858.CD007362.pub2. PMID 19821409
	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]]

Ostermayer: Created page with "==Administration== Type/Class: γ-cyclodextrin Dosage Forms: 200mg/2mL (100mg/mL) 500mg/5mL (100mg/mL) Routes of Administration: IV Common Trade Names: Bridion ==Adu..."

2016-12-07T17:15:32Z

Created page with "==Administration== *Type/Class: γ-cyclodextrin *Dosage Forms: **200mg/2mL (100mg/mL) **500mg/5mL (100mg/mL) *Routes of Administration: IV *Common Trade Names: Bridion ==Adu..."

Página nueva

==Administration==
*Type/Class: γ-cyclodextrin
*Dosage Forms:
**200mg/2mL (100mg/mL)
**500mg/5mL (100mg/mL)
*Routes of Administration: IV
*Common Trade Names: Bridion

==Adult Dosing==
'''IV bolus injection infused over 10 seconds via central or peripheral line with 16 mg/kg will reverse a single 1.2 mg/kg dose of rocuronium in approximately 3 minutes.'''
*4 mg/kg if patient has no twitch responses to train-of-four and emergent reverse is not needed
*2mg/kg if patient has a second twitch after train of four and no emergent reversal is needed
==Pediatric Dosing==
*No approved dosing or usage
==Special Populations==
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: There are no data on use in pregnant women
*[[Lactation risk categories|Lactation risk]]: Unknown
===Renal Dosing===
*Adult: Unknown
*Pediatric: Unknown
===Hepatic Dosing===
*Adult: Unknown
*Pediatric: Unknown

==Contraindications==
*Allergy to class/drug and or prior documentation of hypersensitivity

==Adverse Reactions==
Adverse affects are described in the anesthesia literature and the most serious side effect is in patients with a known hypersensitivity to Sugammadex<ref>Park J. Benefits and risks of sugammadex. Korean J Anesthesiol. 2015 Feb; 68(1): 1–2.</ref>
===Serious===
*Anaphylaxis (0.3%)
*Bradycardia (1-5%)

===Minor===
*Coughing
*Extremity pain
*Parosmia
*Hypoesthesia

==Pharmacology==
Sugammadex can encapsulates rocuronium and vecuronium preventing binding to acetylcholine receptors and can reverse paralysis in 3 minutes.
*Half-life:
*Metabolism:
*Excretion:
==Mechanism of Action==
Sugammadex is a reversal agent that can bind to rocuronium and reverse paralysis. The molecule encapsulates rocuronium rather than reversing paralysis via inhibition of [[acetylcholinesterase]] like [[neostigmine]]. The main use is in reversal of [[rocuronium]] or [[vecuronium]] induced paralysis after surgery<ref>Abrishami A et al. "Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade". Cochrane Database of Systematic Reviews. 2009(4). CD007362. doi:10.1002/14651858.CD007362.pub2. PMID 19821409</ref>
==Comments==
*Sugammadex is only FDA approved for reversal for patients undergoing surgery. The drug has been used in Europe since 2008<ref>[http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000885/WC500052309.pdf Assessment Report for Bridion. European Medicines Agency]</ref>
==See Also==

==References==
<references/>
[[Category:Pharmacology]]